165 related articles for article (PubMed ID: 38607373)
21. Expansion of pulmonary CD8+CD56+ natural killer T-cells in hypersensitivity pneumonitis.
Korosec P; Osolnik K; Kern I; Silar M; Mohorcic K; Kosnik M
Chest; 2007 Oct; 132(4):1291-7. PubMed ID: 17646229
[TBL] [Abstract][Full Text] [Related]
22. Clinical Outcomes of Immune Checkpoint Inhibitor Therapy in Patients With Advanced Non-small Cell Lung Cancer and Preexisting Interstitial Lung Diseases: A Systematic Review and Meta-analysis.
Zhang M; Fan Y; Nie L; Wang G; Sun K; Cheng Y
Chest; 2022 Jun; 161(6):1675-1686. PubMed ID: 35026298
[TBL] [Abstract][Full Text] [Related]
23. Survival and soluble immune mediators of immune checkpoint inhibitor-induced interstitial lung disease in patients with non-small cell lung cancer.
Murata D; Azuma K; Murotani K; Matsuo N; Matama G; Tokito T; Sasada T; Hoshino T
Lung Cancer; 2023 Oct; 184():107351. PubMed ID: 37639819
[TBL] [Abstract][Full Text] [Related]
24. Risk factors for pneumonitis in patients with non-small cell lung cancer treated with immune checkpoint inhibitors plus chemotherapy: A retrospective analysis.
Yamaguchi T; Shimizu J; Oya Y; Watanabe N; Hasegawa T; Horio Y; Inaba Y; Fujiwara Y
Thorac Cancer; 2022 Mar; 13(5):724-731. PubMed ID: 35044093
[TBL] [Abstract][Full Text] [Related]
25. Distinct Expression of Coinhibitory Molecules on Alveolar T Cells in Patients With Rheumatoid Arthritis-Associated and Idiopathic Inflammatory Myopathy-Associated Interstitial Lung Disease.
Nakazawa M; Suzuki K; Takeshita M; Inamo J; Kamata H; Ishii M; Oyamada Y; Oshima H; Takeuchi T
Arthritis Rheumatol; 2021 Apr; 73(4):576-586. PubMed ID: 33038063
[TBL] [Abstract][Full Text] [Related]
26. Are immune checkpoint inhibitors safe and effective in lung cancer patients with pre-existing interstitial lung disease?
Zhu L; Gao R; Li H; Zheng Y; Yang J
Immunotherapy; 2024 Apr; 16(7):465-480. PubMed ID: 38511241
[TBL] [Abstract][Full Text] [Related]
27. Bronchoalveolar Lavage Fluid Reflects a T
Friedmann D; Unger S; Keller B; Rakhmanov M; Goldacker S; Zissel G; Frye BC; Schupp JC; Prasse A; Warnatz K
Front Immunol; 2020; 11():616832. PubMed ID: 33613543
[TBL] [Abstract][Full Text] [Related]
28. Clinical significance of interstitial lung abnormalities and immune checkpoint inhibitor-induced interstitial lung disease in patients with non-small cell lung cancer.
Murata D; Azuma K; Matama G; Zaizen Y; Matsuo N; Murotani K; Tokito T; Hoshino T
Thorac Cancer; 2023 Jan; 14(1):73-80. PubMed ID: 36377039
[TBL] [Abstract][Full Text] [Related]
29. Outcomes of Patients With Interstitial Lung Disease Receiving Programmed Cell Death 1 Inhibitors: A Retrospective Case Series.
Dobre IA; Frank AJ; D'Silva KM; Christiani DC; Okin D; Sharma A; Montesi SB
Clin Lung Cancer; 2021 Sep; 22(5):e738-e744. PubMed ID: 33663958
[TBL] [Abstract][Full Text] [Related]
30. Immune checkpoint inhibitor-related interstitial lung disease in patients with advanced non-small cell lung cancer: systematic review of characteristics, incidence, risk factors, and management.
Kim S; Lim JU
J Thorac Dis; 2022 May; 14(5):1684-1695. PubMed ID: 35693611
[TBL] [Abstract][Full Text] [Related]
31. Circulating and Pulmonary T-cell Populations Driving the Immune Response in Non-HIV Immunocompromised Patients with
Zhang NN; Huang X; Feng HY; Huang LN; Xia JG; Wang Y; Zhang Y; Wu XJ; Li M; Cui W; Zhan QY
Int J Med Sci; 2019; 16(9):1221-1230. PubMed ID: 31588187
[No Abstract] [Full Text] [Related]
32. Immune alveolitis in interstitial lung disease: an attractive cytological profile in immunocompromised patients.
Moui A; Dirou S; Sagan C; Liberge R; Defrance C; Arrigoni PP; Morla O; Kandel-Aznar C; Cellerin L; Cavailles A; Eschapasse E; Morio F; Gourraud PA; Goronflot T; Tissot A; Blanc FX
BMC Pulm Med; 2022 Mar; 22(1):79. PubMed ID: 35247991
[TBL] [Abstract][Full Text] [Related]
33. Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer.
Nakanishi Y; Masuda T; Yamaguchi K; Sakamoto S; Horimasu Y; Nakashima T; Miyamoto S; Tsutani Y; Iwamoto H; Fujitaka K; Miyata Y; Hamada H; Okada M; Hattori N
Respir Investig; 2019 Sep; 57(5):451-459. PubMed ID: 31248832
[TBL] [Abstract][Full Text] [Related]
34. Association of Preexisting Interstitial Lung Abnormalities With Immune Checkpoint Inhibitor-Induced Interstitial Lung Disease Among Patients With Nonlung Cancers.
Shimoji K; Masuda T; Yamaguchi K; Sakamoto S; Horimasu Y; Nakashima T; Miyamoto S; Iwamoto H; Fujitaka K; Hamada H; Takeno S; Hide M; Teishima J; Ohdan H; Hattori N
JAMA Netw Open; 2020 Nov; 3(11):e2022906. PubMed ID: 33180128
[TBL] [Abstract][Full Text] [Related]
35. TNF-α inhibitor ameliorates immune-related arthritis and pneumonitis in humanized mice.
Gao J; Miao J; Sun H; Fu X; Zhang P; Chen Z; Zhu P
Front Immunol; 2022; 13():955812. PubMed ID: 36016934
[TBL] [Abstract][Full Text] [Related]
36. Immune Checkpoint Inhibitor-Induced Thyroiditis Is Associated with Increased Intrathyroidal T Lymphocyte Subpopulations.
Kotwal A; Gustafson MP; Bornschlegl S; Kottschade L; Delivanis DA; Dietz AB; Gandhi M; Ryder M
Thyroid; 2020 Oct; 30(10):1440-1450. PubMed ID: 32323619
[No Abstract] [Full Text] [Related]
37. Immune Checkpoint Inhibitor Therapy-related Pneumonitis: Patterns and Management.
Kalisz KR; Ramaiya NH; Laukamp KR; Gupta A
Radiographics; 2019; 39(7):1923-1937. PubMed ID: 31584861
[TBL] [Abstract][Full Text] [Related]
38. Anti-PD-1-Related Exacerbation of Interstitial Lung Disease in a Patient with Non-Small Cell Lung Cancer: A Case Presentation and Review of the Literature.
L Gemmill JA; Sher A
Cancer Invest; 2020 Jul; 38(6):365-371. PubMed ID: 32559143
[TBL] [Abstract][Full Text] [Related]
39. The utility of ground-glass attenuation score for anticancer treatment-related acute exacerbation of interstitial lung disease among lung cancer patients with interstitial lung disease.
Nishiyama N; Honda T; Sema M; Kawahara T; Jin Y; Natsume I; Chiaki T; Yamashita T; Tsukada Y; Taki R; Miyashita Y; Saito K; Tateishi T; Sakashita H; Miyazaki Y
Int J Clin Oncol; 2020 Feb; 25(2):282-291. PubMed ID: 31720993
[TBL] [Abstract][Full Text] [Related]
40. Pulmonary toxicity of systemic lung cancer therapy.
Long K; Suresh K
Respirology; 2020 Nov; 25 Suppl 2():72-79. PubMed ID: 32729207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
